Fleischer, L., Kirchhoff, H., Schoenherr, C., Heidenreich, O., Scherr, M. and Eder, M. (2020) “Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2026.300519.